Koi Biotherapeutics Inc
- Biotech or pharma, therapeutic R&D
Koi Biotx, a spin-off from Dana-Farber/Harvard Medical School, has developed a novel CAR-Enhancer platform that leverages a protein and will be administered a few weeks after standard CAR T-cell therapy. CAR-Enhancer enhances activity and persistence of CAR T-cells by targeting the CAR molecule and selectively driving CAR T-cells toward the generation of memory CAR T-cells.
Backed by over $3M in academic grants and a 2024 publication in Nature Biotechnology, Koi has secured exclusive IP rights with four patents filed. Our lead program was recently selected for the NIH NeXT program, under which NIH will fully support and execute all key milestones needed to reach IND approval through Dana-Farber. We’re now raising $5.2M in seed funding to support licensing, IND filing, and to run a Phase I trial.
Address
BostonMassachusetts
United States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}